United States

Profile: Palatin Technologies Inc (PTN)

PTN on American Stock Exchange

21 May 2019
Change (% chg)

$0.09 (+5.81%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Palatin Technologies, Inc., incorporated on November 21, 1986, is a biopharmaceutical company. The Company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company's primary product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD), which is a type of female sexual dysfunction (FSD) defined as low desire with associated distress. Its other drug development programs include Melanocortin receptor-4 (MC4r), PL-3994 and Melanocortin receptor-1 (MC1r). In addition, it has drug candidates or development programs for obesity, erectile dysfunction, cardiovascular diseases, pulmonary diseases, inflammatory diseases and dermatologic diseases.


Bremelanotide is a melanocortin agonist, a synthetic peptide analog of a naturally occurring hormone called alpha-MSH. The mechanism of action involves helping to activate internal pathways involved in the body's normal sexual responses. Bremelanotide is in Phase III clinical trials for a type of FSD with decreased sexual desire that is also known as HSDD.

Melanocortin receptor-4

MC4r is a compound used for treatment of obesity and diabetes. The Company is engaged in preclinical activities with MC4r compounds, and is evaluating pharmaceutical applications. It has selected an internal lead compound for obesity, designated PL-8905, which has over 100-fold functional selectivity for MC4r over MC1r with minimal effect on blood pressure and limited central nervous system penetration.


The Company's heart failure product candidate is PL-3994. PL-3994 is a subcutaneously injected guanylate-cyclase type A (GC-A) receptor agonist. It is in development for patients with heart failure to reduce the risk of cardiovascular death and hospitalization. PL-3994 is also being developed for heart failure patients with a loss-of-function corin mutation or other clinically meaningful natriuretic peptide system deficiencies, a patient population that is particularly resistant to the current standard of care. Its heart failure program is focused on the natriuretic peptide receptor system. It is developing synthetic mimetics of natural neuropeptide hormones, including mimetics of atrial natriuretic peptide and other natriuretic peptides.

Melanocortin receptor-1

MC1r agonist peptides are used for treatment of inflammatory and dermatologic disease indications. The Company is conducting preclinical animal studies with its MC1r peptide drug candidates for various indications, primarily inflammatory disease-related and autoimmune indications. The MC1r is upregulated in various diseases, including inflammatory bowel disease, nephritis (inflammation of the kidneys), rheumatoid arthritis, ocular indications, such as uveitis and dry eye, and dermatologic indications.

Company Address

Palatin Technologies Inc

4B Cedarbrook Dr
CRANBURY   NJ   08512-3641
P: +1609.4952200
F: +1609.4952202

Company Web Links